In a randomized double-blind trial of patients with T2D and NAFLD, the group treated with obeticholic acid, a natural agonist of FXR, exhibited significantly lower AST and ALT values, increased insulin sensitivity, and improved hepatic fibrosis compared to a placebo [182]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.